Children's ibuprofen recall: FDA issues notice for Taro Pharmaceuticals' product
Read Original Source
A sign for the U.S. Food and Drug Administration is displayed outside their offices in Silver Spring, Md., Dec. 10, 2020. (AP Photo/Manuel Balce Ceneta, File) WASHINGTON (AP) — Nearly 90,000 bottles of a children’s pain reliever have been recalled due to reports of black specs and other contaminants, according to federal regulators. The Food and Drug Administration posted an online notice about the recall of Taro Pharmaceuticals’ Children’s Ibuprofen Oral Suspension.
AI Summary
Main Idea: The FDA said nearly 90,000 bottles of Taro Pharmaceuticals’ children’s ibuprofen were recalled after reports of black specks and other contaminants.
Key Points:
- The recall covers Children’s Ibuprofen Oral Suspension, a berry-flavored medicine for children ages 2 to 11.
- Customers reported a gel-like mass and black particles in the product.
- Federal regulators said the chance of serious harm is remote.
- The medicine was made in India by Strides Pharma Inc., which started the recall.
Impact on the People
Negative Impact
Families may need to check medicine bottles and replace recalled children’s ibuprofen, which can cause worry and small added costs.
Positive Impact
FDA recall notice may prevent harm by warning parents before most children use the tainted product.
How did each entity affect people?
Rate how each entity in this article affected the American people.
- Major:Strides Pharma Inc.company
Candidate Entities2 candidates · 5 weighted vote min · 70% decision
- Strides Pharma Inc.companyMajorEvaluated
Manufacturer that initiated the recall and is a major accountable actor in the story.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Food and Drug Administrationgovernment agency or bodyPrimaryAI selected
Central regulator that issued the recall notice and assessed the risk.
Include 0 (0%)Ignore 0 (0%)5 to threshold
Comments 0
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to comment